Çek Cumhuriyeti - Çekçe - SUKL (Státní ústav pro kontrolu léčiv)

berlin-chemie ag, berlín array - 3275 prÁŠkovÝ pankreatin - enterosolventní tableta - 20000iu - multienzymovÉ pŘÍpravky (lipasa, proteasa apod.)

Çek Cumhuriyeti - Çekçe - SUKL (Státní ústav pro kontrolu léčiv)

axonia, a.s., praha array - 15455 prÁŠkovÝ cholekalciferol - potahovaná tableta - 1000iu - cholekalciferol

Çek Cumhuriyeti - Çekçe - SUKL (Státní ústav pro kontrolu léčiv)

axonia, a.s., praha array - 15455 prÁŠkovÝ cholekalciferol - potahovaná tableta - 30000iu - cholekalciferol

Çek Cumhuriyeti - Çekçe - SUKL (Státní ústav pro kontrolu léčiv)

axonia, a.s., praha array - 15455 prÁŠkovÝ cholekalciferol - potahovaná tableta - 7000iu - cholekalciferol

Çek Cumhuriyeti - Çekçe - SUKL (Státní ústav pro kontrolu léčiv)

orifarm healthcare a/s, odense array - 234 uhliČitan vÁpenatÝ; 15455 prÁŠkovÝ cholekalciferol - Žvýkací tableta - 500mg/400iu - vÁpnÍk, kombinace s vitaminem d a/nebo jinÝmi lÉČivy

Çek Cumhuriyeti - Çekçe - SUKL (Státní ústav pro kontrolu léčiv)

baxalta innovations gmbh, vídeň array - 5167 normÁlnÍ lidskÝ imunoglobulin pro intravenÓznÍ podÁnÍ - prášek a rozpouštědlo pro infuzní roztok - 50mg/ml - imunoglobuliny, normÁlnÍ lidskÉ, pro intravaskulÁrnÍ aplikaci

Çek Cumhuriyeti - Çekçe - SUKL (Státní ústav pro kontrolu léčiv)

baxalta innovations gmbh, vídeň array - 3532 protrombin; 3534 lidskÝ koagulaČnÍ faktor vii; 1990 lidskÝ koagulaČnÍ faktor ix; 2218 lidskÝ koagulaČnÍ faktor x; 3719 proteiny - prášek a rozpouštědlo pro injekční roztok - 600iu - kombinace koagulaČnÍch faktorŮ ix, ii, vii a x

Avrupa Birliği - Çekçe - EMA (European Medicines Agency)

bayer ag - octocog alfa - hemofilie a - antihemoragika - léčba a profylaxe krvácení u pacientů s hemofilií a (vrozený nedostatek faktoru viii). iblias může být použit pro všechny věkové skupiny.

Avrupa Birliği - Çekçe - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - artritida, revmatoidní - imunosupresiva - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 a 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Avrupa Birliği - Çekçe - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. viz kapitoly 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.